What recent pembrolizumab/enfortumab vedotin data mean for treatment of metastatic urothelial cancer
September 18th 2022“These data do suggest that [enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)] is a viable treatment option for cisplatin-ineligible patients,” says Jonathan E. Rosenberg, MD.
Dr. Rosenberg discusses pembrolizumab/enfortumab vedotin combo for urothelial cancer
September 15th 2022“There were no serious skin events that occurred on this study, which I think is a credit to the study team that worked with the investigators to manage the manage the toxicity and prevent serious skin reactions,” says Jonathan E. Rosenberg, MD.
Blood-based assay shows promise in detecting liquid and solid tumors, including prostate cancer
September 15th 2022"When the blood tests were positive, workups were typically completed in less than 3 months. I think this is really a new concept. It shows it is feasible to detect cancers using blood tests," said Deb Schrag, MD, MPH.
Olaparib addition to frontline abiraterone continues to show superior outcomes in mCRPC
September 11th 2022“Updated results [from the] second interim analysis were consistent with the results from [the first analysis] and showed a continuing trend toward an OS benefit in the ITT population," said Fred Saad, MD, FRCS.
Lenvatinib/pembrolizumab efficacy in renal cell carcinoma sustained with longer follow-up
September 11th 2022“These data clearly show that the efficacy benefit observed at the primary analysis was robust and maintained with longer follow-up, once again supporting lenvatinib and pembrolizumab as a standard of care in first-line advanced RCC,” said Camillo G. Porta, MD.
Cabazitaxel linked to lower treatment costs in third-line mCRPC
October 18th 2021Alicia Morgans, MD, MPH, discusses a health economics analysis that assessed the clinical and cost impact of cabazitaxel (Jevtana) as a third-line treatment for patients with metastatic castration-resistant prostate cancer.
Dr. Schweizer on olaparib plus bipolar androgen therapy in mCRPC
September 27th 2021“The activity that we saw with the combination was very promising and…it justifies additional clinical trials to determine whether or not this could have a place in terms of our standard treatment options for patients,” says Michael Schweizer, MD.
Adding abiraterone to ADT/docetaxel may be new standard in de novo mCSPC
September 20th 2021Adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel may be the new standard of care for the treatment of patients with de novo metastatic castration-sensitive prostate cancer.
2-year data for abiraterone regimen show sustained OS benefit in nonmetastatic prostate cancer
September 19th 2021"2 years of abiraterone-based therapy significantly improves metastasis-free survival and overall survival of high-risk nonmetastatic prostate cancer starting androgen deprivation therapy and should be now considered a new standard of care,” said Gerhardt Attard, MD, FRCP, PhD.